J7637 HCPCS code: Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
J7637 is the HCPCS Level II code for dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | D1G — Drugs administered through DME |
| Added | 2000-01-01 |
| Last action effective | 2007-01-01 |
What changed for J7637
- 2000-01-01: J7637 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7637?
J7637 is the HCPCS Level II code for dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram. Short descriptor: "Dexamethasone comp con".
Does Medicare cover J7637?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Related J76 codes
- J7601 — Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
- J7604 — Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
- J7605 — Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
- J7606 — Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
- J7607 — Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mg
- J7608 — Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
- J7609 — Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg
- J7610 — Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg
- J7611 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg
- J7612 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
- J7613 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg
- J7614 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7637
- Watch J7637 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7637
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.